Sylvie Brailly-Tabard
Overview
Explore the profile of Sylvie Brailly-Tabard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonen N, Eozenou C, Mitter R, Elzaiat M, Stevant I, Aviram R, et al.
Sci Adv
. 2023 Jan;
9(1):eabn9793.
PMID: 36598988
During embryonic development, mutually antagonistic signaling cascades determine gonadal fate toward a testicular or ovarian identity. Errors in this process result in disorders of sex development (DSDs), characterized by discordance...
2.
Maione L, Sarfati J, Gonfroy-Leymarie C, Salenave S, Brailly-Tabard S, Chanson P, et al.
J Clin Endocrinol Metab
. 2022 Mar;
107(7):e2812-e2824.
PMID: 35358314
Context: In men with congenital hypogonadotropic hypogonadism (CHH), gonadotropin deficiency and testicular impairment exist since fetal development and persist throughout life. In a few reported cases of acquired HH (AHH),...
3.
Motte-Signoret E, Shankar-Aguilera S, Brailly-Tabard S, Soreze Y, Dell Orto V, Ben Ammar R, et al.
Front Pediatr
. 2021 Aug;
9:711400.
PMID: 34447729
To investigate the impact of fetal growth restriction (FGR) on hormonal regulation of post-natal growth and glucose metabolism [via insulin and growth hormone (GH)/Insulin-like Growth factor 1 (IGF1) axis pathways]...
4.
Mosbah H, Bouvattier C, Maione L, Trabado S, DE Filippo G, Cartes A, et al.
Hum Reprod
. 2020 Aug;
35(10):2312-2322.
PMID: 32862222
Study Question: Are GnRH tests and serum inhibin B levels sufficiently discriminating to distinguish transient constitutional delay of growth and puberty (CDGP) from congenital hypogonadotropic hypogonadism (CHH) that affects reproductive...
5.
Corvest V, Lemaire P, Brailly-Tabard S, Brauner R
Front Pediatr
. 2020 Jun;
8:304.
PMID: 32596193
In patients with pituitary stalk interruption syndrome (PSIS), long-term follow-up is necessary to address their gonadotrophic status. The objectives of this study were (1) to describe pubertal features of and...
6.
Laouali N, Brailly-Tabard S, Helmer C, Ancelin M, Tzourio C, Elbaz A, et al.
Epidemiol Health
. 2020 Jun;
42:e2020036.
PMID: 32512663
Objectives: Previous studies have reported controversial findings regarding the association of testosterone with mortality in older men. This heterogeneity might be partially explained by comorbidities and the presence of metabolic...
7.
Lecoq A, Chaumet-Riffaud P, Blanchard A, Dupeux M, Rothenbuhler A, Lambert B, et al.
J Bone Miner Res
. 2020 Feb;
35(7):1263-1273.
PMID: 32101626
X-linked hypophosphatemia (XLH) is characterized by increased activity of circulating FGF23 resulting in renal phosphate wasting and abnormal bone mineralization. Hyperparathyroidism may develop in XLH patients; however, its prevalence, pathogenesis,...
8.
Kamenicky P, Blanchard A, Lamaziere A, Piedvache C, Donadille B, Duranteau L, et al.
J Clin Endocrinol Metab
. 2019 Sep;
105(1).
PMID: 31529070
Background: Non-classic 21-hydroxylase deficiency is usually diagnosed in post-pubertal women because of androgen excess. Indication of systematic steroid replacement therapy is controversial because the risk of acute adrenal insufficiency is...
9.
Tencer J, Lemaire P, Brailly-Tabard S, Brauner R
PLoS One
. 2018 Dec;
13(12):e0205810.
PMID: 30550563
Objective: To compare the serum inhibin B, anti-Müllerian hormone (AMH) and leptin concentrations in girls with idiopathic central precocious puberty (CPP) to their concomitant characteristics and evaluate the capacity of...
10.
Briet C, Ilie M, Kuhn E, Maione L, Brailly-Tabard S, Salenave S, et al.
Endocrine
. 2018 Nov;
63(2):348-360.
PMID: 30397873
Context: Untreated acromegaly is associated with increased morbidity and mortality due to malignant, cardiovascular, and cerebrovascular disorders. Effective treatment of acromegaly reduces excess mortality, but its impact on cardiovascular risk...